-
1
-
-
36049015455
-
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Protocol 9911
-
Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25:4800-4805.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4800-4805
-
-
Langer, C.J.1
Harris, J.2
Horwitz, E.M.3
-
2
-
-
0033017066
-
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer
-
Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-1379.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 1369-1379
-
-
Chen, Z.1
Malhotra, P.S.2
Thomas, G.R.3
-
3
-
-
0035529049
-
Constitutive NFkappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines
-
Didelot C, Barberi-Heyob M, Bianchi A, et al. Constitutive NFkappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines. Int J Radiat Oncol Biol Phys 2001;51:1354-1360.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.51
, pp. 1354-1360
-
-
Didelot, C.1
Barberi-Heyob, M.2
Bianchi, A.3
-
4
-
-
35348918435
-
A novel NF-kB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status
-
Lee TL, Yang XP, Yan B, et al. A novel NF-kB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007;13:5680-5691.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5680-5691
-
-
Lee, T.L.1
Yang, X.P.2
Yan, B.3
-
5
-
-
20444433230
-
Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
-
6
-
-
7644242953
-
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
-
Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-9704.
-
(2004)
Mol Cell Biol
, vol.24
, pp. 9695-9704
-
-
Fribley, A.1
Zeng, Q.2
Wang, C.Y.3
-
7
-
-
34247390711
-
Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation
-
Weber CN, Cerniglia GJ, Maity A, et al. Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 2007;6:156-159.
-
(2007)
Cancer Biol Ther
, vol.6
, pp. 156-159
-
-
Weber, C.N.1
Cerniglia, G.J.2
Maity, A.3
-
8
-
-
27744515028
-
Inhibition of nuclear factor-kb and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
-
Waes CV, Chang AA, Lebowitz PF. Inhibition of nuclear factor-kb and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63: 1400-1412.
-
(2005)
Int J Radiat Oncol Biol Phys
, vol.63
, pp. 1400-1412
-
-
Waes, C.V.1
Chang, A.A.2
Lebowitz, P.F.3
-
9
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
10
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
11
-
-
34247855046
-
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327)
-
Lara PN Jr., Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006;9:996-1001.
-
(2006)
J Thorac Oncol
, vol.9
, pp. 996-1001
-
-
Lara Jr., P.N.1
Chansky, K.2
Davies, A.M.3
-
12
-
-
33750945704
-
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
-
Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-5033.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5025-5033
-
-
Fanucchi, M.P.1
Fossella, F.V.2
Belt, R.3
-
13
-
-
33751563004
-
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
-
Ryan DP, O'Neil BH, Supko JG, et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006; 107:2688-2697.
-
(2006)
Cancer
, vol.107
, pp. 2688-2697
-
-
Ryan, D.P.1
O'Neil, B.H.2
Supko, J.G.3
-
14
-
-
67349138194
-
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
-
Kubicek GJ, Werner-Wasik M, Machtay M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009;74:433-439.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.74
, pp. 433-439
-
-
Kubicek, G.J.1
Werner-Wasik, M.2
Machtay, M.3
-
15
-
-
79951716964
-
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies
-
Pugh TJ, Chen C, Rabinovitch R, et al. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys 2010;78:521-526.
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.78
, pp. 521-526
-
-
Pugh, T.J.1
Chen, C.2
Rabinovitch, R.3
-
16
-
-
33750976204
-
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
-
Ryan DP, Appleman LJ, Lynch T, et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006;107:2482-2489.
-
(2006)
Cancer
, vol.107
, pp. 2482-2489
-
-
Ryan, D.P.1
Appleman, L.J.2
Lynch, T.3
-
17
-
-
61549138750
-
Bortezomib plus gemcitabine/ carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group Study (S0339)
-
Davies AM, Chansky K, Lara PN, et al. Bortezomib plus gemcitabine/ carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009;4:87-92.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 87-92
-
-
Davies, A.M.1
Chansky, K.2
Lara, P.N.3
-
18
-
-
33846685893
-
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer
-
Lorch JH, Thomas TO, Schmoll HJ. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 2007;67:727-734.
-
(2007)
Cancer Res
, vol.67
, pp. 727-734
-
-
Lorch, J.H.1
Thomas, T.O.2
Schmoll, H.J.3
|